The Ministry of Food and Drug Safety (Minister Oh Yu-kyoung, MFDS) announced on December 31 that it has approved 'Voxzogo (vosritid),' an orphan drug used to treat achondroplasia in children over four months whose growth plates are not closed.

Achondroplasia is a bone growth-related genetic disease caused by a mutation in the FGFR3, a gene regulating cartilage cell proliferation and division.

This drug suppresses the overactivation of FGFR3 (fibroblast growth factor receptor 3) in children with achondroplasia, inducing proliferation and division of cartilage cells, ultimately stimulating bone formation within the cartilage.

Previously, there were no treatments available